Beyond Air announced the first patient to be enrolled in a COVID-19 treatment study using the LungFit system, which uses inhaled NO oxide generated from ambient air to deliver accurate amounts of NO to patients' lungs. A total of 20 participants are planned for the study. The company hopes for a positive result of clinical trials of this technology in the treatment of various lung diseases such as coronavirus, bronchiolitis and non-tuberculosis mycobacteria.